Shopping Cart
- Remove All
- Your shopping cart is currently empty
Amivantamab (JNJ-61186372) is a humanized antibody that recognizes epidermal growth factor receptor (EGFR) and MET proto-oncogene (MET), with anticancer and anti-tumor activities, preventing ligand binding to EGFR and MET and receptor dimerization that inhibits downstream signal transduction. Amivantamab can induce Fc-dependent endocytosis of macrophages and antibody-dependent cytotoxicity of natural killer cells, and can be used to study metastatic non-small cell lung cancer.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $289 | In Stock | |
5 mg | $787 | In Stock | |
10 mg | $1,260 | In Stock |
Description | Amivantamab (JNJ-61186372) is a humanized antibody that recognizes epidermal growth factor receptor (EGFR) and MET proto-oncogene (MET), with anticancer and anti-tumor activities, preventing ligand binding to EGFR and MET and receptor dimerization that inhibits downstream signal transduction. Amivantamab can induce Fc-dependent endocytosis of macrophages and antibody-dependent cytotoxicity of natural killer cells, and can be used to study metastatic non-small cell lung cancer. |
In vitro | In Ba/F3 cells treated with Amivantamab ranging from 0.05 to 1 mg/mL, a significant and dose dependent decrease in Ba/F3 cell viability (P < 0.0001) was observed in all five EGFR Exon20ins mutations. [1] |
In vivo | Mice were treated with amivantamab, IgG1 control, or vehicle at 30 mg/kg twice per week intraperitoneally. Amivantamab-treated mice showed reduced tumor volumes in the Ba/F3 cells bearing NOD. [1] |
Alias | JNJ-61186372, JNJ61186372, JNJ 61186372 |
Molecular Weight | 145.88 kDa |
Cas No. | 2171511-58-1 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.